PortfoliosLab logo
VIR vs. CRT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between VIR and CRT is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

VIR vs. CRT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vir Biotechnology, Inc. (VIR) and Cross Timbers Royalty Trust (CRT). The values are adjusted to include any dividend payments, if applicable.

-50.00%0.00%50.00%100.00%150.00%December2025FebruaryMarchAprilMay
-56.06%
113.64%
VIR
CRT

Key characteristics

Sharpe Ratio

VIR:

-0.31

CRT:

-0.44

Sortino Ratio

VIR:

0.06

CRT:

-0.40

Omega Ratio

VIR:

1.01

CRT:

0.95

Calmar Ratio

VIR:

-0.29

CRT:

-0.27

Martin Ratio

VIR:

-0.79

CRT:

-0.76

Ulcer Index

VIR:

34.46%

CRT:

23.42%

Daily Std Dev

VIR:

89.03%

CRT:

40.74%

Max Drawdown

VIR:

-93.75%

CRT:

-83.46%

Current Drawdown

VIR:

-92.58%

CRT:

-59.81%

Fundamentals

Market Cap

VIR:

$839.43M

CRT:

$60.66M

EPS

VIR:

-$3.83

CRT:

$0.95

PS Ratio

VIR:

11.31

CRT:

9.53

PB Ratio

VIR:

0.73

CRT:

25.94

Total Revenue (TTM)

VIR:

$16.73M

CRT:

$4.74M

Gross Profit (TTM)

VIR:

$11.69M

CRT:

$7.89M

EBITDA (TTM)

VIR:

-$462.00M

CRT:

$4.23M

Returns By Period

In the year-to-date period, VIR achieves a -16.08% return, which is significantly lower than CRT's 4.51% return.


VIR

YTD

-16.08%

1M

-4.94%

6M

-33.48%

1Y

-32.90%

5Y*

-26.12%

10Y*

N/A

CRT

YTD

4.51%

1M

-14.28%

6M

6.50%

1Y

-17.81%

5Y*

21.89%

10Y*

0.64%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VIR vs. CRT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VIR
The Risk-Adjusted Performance Rank of VIR is 3636
Overall Rank
The Sharpe Ratio Rank of VIR is 3434
Sharpe Ratio Rank
The Sortino Ratio Rank of VIR is 3838
Sortino Ratio Rank
The Omega Ratio Rank of VIR is 3838
Omega Ratio Rank
The Calmar Ratio Rank of VIR is 3333
Calmar Ratio Rank
The Martin Ratio Rank of VIR is 3434
Martin Ratio Rank

CRT
The Risk-Adjusted Performance Rank of CRT is 3030
Overall Rank
The Sharpe Ratio Rank of CRT is 2727
Sharpe Ratio Rank
The Sortino Ratio Rank of CRT is 2626
Sortino Ratio Rank
The Omega Ratio Rank of CRT is 2727
Omega Ratio Rank
The Calmar Ratio Rank of CRT is 3535
Calmar Ratio Rank
The Martin Ratio Rank of CRT is 3535
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VIR vs. CRT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Cross Timbers Royalty Trust (CRT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for VIR, currently valued at -0.31, compared to the broader market-2.00-1.000.001.002.003.00
VIR: -0.31
CRT: -0.44
The chart of Sortino ratio for VIR, currently valued at 0.06, compared to the broader market-6.00-4.00-2.000.002.004.00
VIR: 0.06
CRT: -0.40
The chart of Omega ratio for VIR, currently valued at 1.01, compared to the broader market0.501.001.502.00
VIR: 1.01
CRT: 0.95
The chart of Calmar ratio for VIR, currently valued at -0.29, compared to the broader market0.001.002.003.004.005.00
VIR: -0.29
CRT: -0.27
The chart of Martin ratio for VIR, currently valued at -0.79, compared to the broader market-40.00-30.00-20.00-10.000.0010.0020.00
VIR: -0.79
CRT: -0.76

The current VIR Sharpe Ratio is -0.31, which is higher than the CRT Sharpe Ratio of -0.44. The chart below compares the historical Sharpe Ratios of VIR and CRT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.00December2025FebruaryMarchAprilMay
-0.31
-0.44
VIR
CRT

Dividends

VIR vs. CRT - Dividend Comparison

VIR has not paid dividends to shareholders, while CRT's dividend yield for the trailing twelve months is around 8.87%.


TTM20242023202220212020201920182017201620152014
VIR
Vir Biotechnology, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
CRT
Cross Timbers Royalty Trust
8.87%9.55%10.97%7.69%9.70%9.44%10.05%13.08%6.86%5.90%10.41%15.33%

Drawdowns

VIR vs. CRT - Drawdown Comparison

The maximum VIR drawdown since its inception was -93.75%, which is greater than CRT's maximum drawdown of -83.46%. Use the drawdown chart below to compare losses from any high point for VIR and CRT. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%December2025FebruaryMarchAprilMay
-92.58%
-59.81%
VIR
CRT

Volatility

VIR vs. CRT - Volatility Comparison

Vir Biotechnology, Inc. (VIR) has a higher volatility of 20.87% compared to Cross Timbers Royalty Trust (CRT) at 16.93%. This indicates that VIR's price experiences larger fluctuations and is considered to be riskier than CRT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%December2025FebruaryMarchAprilMay
20.87%
16.93%
VIR
CRT

Financials

VIR vs. CRT - Financials Comparison

This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and Cross Timbers Royalty Trust. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B1.20BAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
11.28M
1.46M
(VIR) Total Revenue
(CRT) Total Revenue
Values in USD except per share items